

DOASENSE rapid test suite for direct oral anticoagulants receives ANVISA approval in Brazil

HEIDELBERG – 03 May 2021 – Further expanding the international availability of its DOAC point-of-care test, DOASENSE today announced that the DOAC Dipstick test suite has received ANVISA registration in Brazil. DOASENSE worked closely with its local partner SUNMEDCARE on the regulatory approval.

The ANVISA registration is another milestone for DOASENSE in making its unique DOAC rapid test available to healthcare professionals around the world. The DOAC Dipstick is the first CE-marked point-of-care test for detecting modern direct oral anticoagulants. With a growing number of users in Europe, Brazil will now have the first users on the American continent who can profit from the test's high sensitivity and specificity, as well as its 24/7 availability.

“We are delighted that the DOAC Dipstick now has ANVISA registration, as the test can play an important role in modern coagulation management. SUNMEDCARE is thrilled to be the company bringing this unique and innovative test to our customers in Brazil” said Ricardo Chamas, Director at SUNMEDCARE.

SUNMEDCARE can be reached at administracao@sunmedcare.com.br and www.sunmedcare.com.br

About the DOASENSE Product Suite:

The CE-marked, ANVISA and TGA registered DOAC Dipstick is a qualitative all-in-one POCT for both direct factor Xa and thrombin inhibitor DOACs. The test is performed using a urine sample from the patient. The DOAC Dipstick provides results within 10 minutes where they are needed most: at the point-of-care. Specially developed accessories complete the first suite of CE-marked products for rapid point-of-care DOAC testing: Objective documentation of results can be achieved with the compact, automated DOASENSE Reader. And the DOASENSE Control Urines are specially designed reference substances to support quality assurance needs. The in vitro diagnostic products are for professional use only.

About DOASENSE:

DOASENSE is a medical technology company with operations in Heidelberg, Germany. DOASENSE's exclusive, patent protected technology changes the way of testing for direct oral anticoagulants, serving an unmet clinical need.

The company is open to distributor inquiries for further broadening the international market presence of its products.

Contact:

DOASENSE GmbH, Waldhofer Str. 102, 69123 Heidelberg, Germany

info@doasense.de

www.doasense.de